Home › Companies › Maravai LifeSciences Holdings, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Maravai LifeSciences Holdings, Inc.’s Form 8-K, filed May 29, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 26, 2026: 5 items on Maravai LifeSciences Holdings, Inc.’s Form 8-K, filed May 29, 2026: 3 elected · 2 approved.
Notable dissent: 2 directors (11.5%, 10.1% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Maravai LifeSciences Holdings, Inc. in the interactive database Compare manager voting policies
These tallies are Maravai LifeSciences Holdings, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 29, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Bernd Brust | 182,998,545 | -- | -- | 19,825,453 | 33,258,969 | 90% | Elected | — |
| Elect Director: Gregory T. Lucier | 179,514,826 | -- | -- | 23,309,172 | 33,258,969 | 89% | Elected | — |
| Elect Director: Luke Marker | 182,239,834 | -- | -- | 20,584,164 | 33,258,969 | 90% | Elected | — |
| 2. Proposal to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 | 234,492,897 | 1,246,939 | 343,132 | -- | -- | 99.5% | Approved | — |
| 3. Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting | 200,054,156 | 2,457,403 | 312,439 | -- | 33,258,969 | 99% | Approved | — |
Source: Maravai LifeSciences Holdings, Inc., Form 8-K, filed with the SEC on May 29, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
162 asset managers disclosed a vote on at least one Maravai LifeSciences Holdings, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: To elect three nominees to the Board of Directors (3-year term expiring in 2029): Bernd Brust
Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Elect Director: Bernd Brust”): 182,998,545 for, 19,825,453 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's shareholders elected the following nominees for director to serve for three-year terms expiring at the Company's 2029 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, or until his or her earlier death, resignation or removal.”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 20,186,507 for, 2,746,063 withheld, 39 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,338,210 | 0 | 39 | 0 | For |
| BlackRock | 3,764,578 | 0 | 0 | 0 | For |
| Fidelity | 2,400,756 | 0 | 0 | 0 | For |
| FIRST EAGLE FUNDS | 0 | 0 | 0 | 2,167,166 | Withhold |
| Royce | 1,808,448 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 1,716,193 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,014,383 | 0 | 0 | 0 | For |
| Charles Schwab | 992,147 | 0 | 0 | 0 | For |
| Goldman Sachs | 381,639 | 0 | 0 | 0 | For |
| Equitable | 253,182 | 0 | 0 | 0 | For |
| TIAA | 228,373 | 0 | 0 | 0 | For |
| Nationwide | 76,386 | 0 | 0 | 147,532 | Mixed |
| Northern Trust | 213,671 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 190,588 | 0 | 0 | 0 | For |
| Transamerica | 184,300 | 0 | 0 | 0 | For |
| Lazard | 137,703 | 0 | 0 | 0 | For |
| EA Series Trust | 90,161 | 0 | 0 | 0 | For |
| Lincoln Financial | 76,300 | 0 | 0 | 9,060 | Mixed |
| Columbia Threadneedle | 82,898 | 0 | 0 | 0 | For |
| Global X | 74,714 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 56,575 | Withhold |
| GuideStone | 0 | 0 | 0 | 54,900 | Withhold |
| Bridge Builder Trust | 49,215 | 0 | 0 | 0 | For |
| Pacific Life | 44,759 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 39,443 | Withhold |
Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: To elect three nominees to the Board of Directors (3-year term expiring in 2029): Gregory T. Lucier
Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Elect Director: Gregory T. Lucier”): 179,514,826 for, 23,309,172 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's shareholders elected the following nominees for director to serve for three-year terms expiring at the Company's 2029 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, or until his or her earlier death, resignation or removal.”
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 19,576,430 for, 3,356,128 withheld, 51 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,322,565 | 0 | 51 | 15,633 | For |
| BlackRock | 3,764,578 | 0 | 0 | 0 | For |
| Fidelity | 2,400,756 | 0 | 0 | 0 | For |
| FIRST EAGLE FUNDS | 0 | 0 | 0 | 2,167,166 | Withhold |
| Royce | 1,808,448 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 1,716,193 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,014,383 | 0 | 0 | 0 | For |
| Charles Schwab | 992,147 | 0 | 0 | 0 | For |
| Goldman Sachs | 381,639 | 0 | 0 | 0 | For |
| Equitable | 161,671 | 0 | 0 | 91,511 | Mixed |
| TIAA | 0 | 0 | 0 | 228,373 | Withhold |
| Nationwide | 76,386 | 0 | 0 | 147,532 | Mixed |
| Northern Trust | 213,671 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 190,588 | 0 | 0 | 0 | For |
| Transamerica | 184,300 | 0 | 0 | 0 | For |
| Lazard | 0 | 0 | 0 | 137,703 | Withhold |
| EA Series Trust | 90,161 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 85,360 | Withhold |
| Columbia Threadneedle | 0 | 0 | 0 | 82,898 | Withhold |
| Global X | 74,714 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 56,575 | Withhold |
| GuideStone | 0 | 0 | 0 | 54,900 | Withhold |
| Bridge Builder Trust | 49,215 | 0 | 0 | 0 | For |
| Pacific Life | 44,759 | 0 | 0 | 0 | For |
| Invesco | 39,443 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: To elect three nominees to the Board of Directors (3-year term expiring in 2029): Luke Marker
Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Elect Director: Luke Marker”): 182,239,834 for, 20,584,164 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's shareholders elected the following nominees for director to serve for three-year terms expiring at the Company's 2029 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, or until his or her earlier death, resignation or removal.”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 19,895,439 for, 3,037,128 withheld, 42 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,327,583 | 0 | 42 | 10,624 | For |
| BlackRock | 3,764,578 | 0 | 0 | 0 | For |
| Fidelity | 2,400,756 | 0 | 0 | 0 | For |
| FIRST EAGLE FUNDS | 0 | 0 | 0 | 2,167,166 | Withhold |
| Royce | 1,808,448 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 1,716,193 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,014,383 | 0 | 0 | 0 | For |
| Charles Schwab | 992,147 | 0 | 0 | 0 | For |
| Goldman Sachs | 381,639 | 0 | 0 | 0 | For |
| Equitable | 161,671 | 0 | 0 | 91,511 | Mixed |
| TIAA | 0 | 0 | 0 | 228,373 | Withhold |
| Nationwide | 76,386 | 0 | 0 | 147,532 | Mixed |
| Northern Trust | 213,671 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 190,588 | 0 | 0 | 0 | For |
| Transamerica | 184,300 | 0 | 0 | 0 | For |
| Lazard | 137,703 | 0 | 0 | 0 | For |
| EA Series Trust | 90,161 | 0 | 0 | 0 | For |
| Lincoln Financial | 76,300 | 0 | 0 | 9,060 | Mixed |
| Columbia Threadneedle | 82,898 | 0 | 0 | 0 | For |
| Global X | 74,714 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 56,575 | Withhold |
| GuideStone | 0 | 0 | 0 | 54,900 | Withhold |
| Bridge Builder Trust | 49,215 | 0 | 0 | 0 | For |
| Pacific Life | 44,759 | 0 | 0 | 0 | For |
| Invesco | 39,443 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
99% Approved · of votes cast
Prior year: 81.9% for (May 22, 2025 meeting) ▲ 16.9 pts
Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF MARAVAI'S NAMED EXECUTIVE OFFICERS.
Maravai LifeSciences Holdings, Inc.’s own tally for this item (“3. Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting”): 200,054,156 for, 2,457,403 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's shareholders approved, on a non-binding and advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,322,608 | 15,640 | 1 | 0 | For |
| BlackRock | 3,764,578 | 0 | 0 | 0 | For |
| Fidelity | 2,400,756 | 0 | 0 | 0 | For |
| FIRST EAGLE FUNDS | 2,167,166 | 0 | 0 | 0 | For |
| Royce | 1,808,448 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 1,716,193 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,014,383 | 0 | 0 | 0 | For |
| Charles Schwab | 992,147 | 0 | 0 | 0 | For |
| Goldman Sachs | 381,639 | 0 | 0 | 0 | For |
| Equitable | 161,671 | 91,511 | 0 | 0 | Mixed |
| TIAA | 228,373 | 0 | 0 | 0 | For |
| Nationwide | 223,918 | 0 | 0 | 0 | For |
| Northern Trust | 213,671 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 190,588 | 0 | 0 | 0 | For |
| Transamerica | 184,300 | 0 | 0 | 0 | For |
| Lazard | 137,703 | 0 | 0 | 0 | For |
| EA Series Trust | 90,161 | 0 | 0 | 0 | For |
| Lincoln Financial | 76,300 | 9,060 | 0 | 0 | Mixed |
| Columbia Threadneedle | 82,898 | 0 | 0 | 0 | For |
| Global X | 74,714 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 56,575 | 0 | 0 | 0 | For |
| GuideStone | 54,900 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 49,215 | 0 | 0 | 0 | For |
| Pacific Life | 44,759 | 0 | 0 | 0 | For |
| Invesco | 0 | 39,443 | 0 | 0 | Against |
Fund voting reports, all 49 managers: 22,676,570 for, 256,038 against, 1 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GTCR LLC | 130,834,085 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 8,324,408 | 0 | 0 | 0 | For |
| 12 West Capital Management LP | 7,260,193 | 0 | 0 | 0 | For |
| MACKENZIE FINANCIAL CORP | 6,306,425 | 0 | 0 | 0 | For |
| Renaissance | 3,516,826 | 0 | 0 | 0 | For |
| BlackRock | 2,645,032 | 390,983 | 0 | 0 | Mixed |
| GEODE CAPITAL MANAGEMENT, LLC | 2,823,673 | 0 | 0 | 0 | For |
| First Eagle Investment Management, LLC | 2,489,336 | 0 | 0 | 0 | For |
| Philosophy Capital Management LLC | 2,462,951 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,069,191 | 0 | 0 | 0 | For |
| State Street | 1,919,660 | 0 | 0 | 0 | For |
| Point72 | 1,367,258 | 0 | 0 | 0 | For |
| Charles Schwab | 992,780 | 0 | 0 | 0 | For |
| First Pacific Advisors, LP | 884,883 | 0 | 0 | 0 | For |
| Vanguard | 826,344 | 0 | 0 | 0 | For |
| Goldman Sachs | 782,619 | 0 | 0 | 0 | For |
| Northern Trust | 777,824 | 0 | 0 | 0 | For |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | 725,481 | 51,003 | 0 | 0 | Mixed |
| Two Sigma | 769,420 | 0 | 0 | 0 | For |
| Citadel | 633,155 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 533,877 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 384,837 | 0 | 0 | 0 | For |
| Dimensional | 0 | 264,013 | 0 | 0 | Against |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 261,866 | 0 | 0 | 0 | For |
| Nuveen | 230,147 | 0 | 0 | 0 | For |
No total is shown for the institutional-manager reports: their sum exceeds the company's reported shares outstanding. Showing the 25 largest; every one is in the interactive database (link above).
99.5% Approved · of votes cast
Prior year: 99.8% for (May 22, 2025 meeting) ▼ 0.3 pts
Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as Maravai's independent registered public accounting firm for the year ending December 31, 2026.
Maravai LifeSciences Holdings, Inc.’s own tally for this item (“2. Proposal to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026”): 234,492,897 for, 1,246,939 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was ratified by the Company's shareholders.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 22,932,608 for, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,338,248 | 0 | 1 | 0 | For |
| BlackRock | 3,764,578 | 0 | 0 | 0 | For |
| Fidelity | 2,400,756 | 0 | 0 | 0 | For |
| FIRST EAGLE FUNDS | 2,167,166 | 0 | 0 | 0 | For |
| Royce | 1,808,448 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 1,716,193 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,014,383 | 0 | 0 | 0 | For |
| Charles Schwab | 992,147 | 0 | 0 | 0 | For |
| Goldman Sachs | 381,639 | 0 | 0 | 0 | For |
| Equitable | 253,182 | 0 | 0 | 0 | For |
| TIAA | 228,373 | 0 | 0 | 0 | For |
| Nationwide | 223,918 | 0 | 0 | 0 | For |
| Northern Trust | 213,671 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 190,588 | 0 | 0 | 0 | For |
| Transamerica | 184,300 | 0 | 0 | 0 | For |
| Lazard | 137,703 | 0 | 0 | 0 | For |
| EA Series Trust | 90,161 | 0 | 0 | 0 | For |
| Lincoln Financial | 85,360 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 82,898 | 0 | 0 | 0 | For |
| Global X | 74,714 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 56,575 | 0 | 0 | 0 | For |
| GuideStone | 54,900 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 49,215 | 0 | 0 | 0 | For |
| Pacific Life | 44,759 | 0 | 0 | 0 | For |
| Invesco | 39,443 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 146,426,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.33% |
| 2 | BlackRock | 2.57% |
| 3 | Fidelity | 1.64% |
| 4 | FIRST EAGLE FUNDS | 1.48% |
| 5 | Royce | 1.24% |
| 6 | GENERAL AMERICAN INVESTORS CO INC | 1.17% |
| 7 | T. Rowe Price | 0.69% |
| 8 | Charles Schwab | 0.68% |
| 9 | Goldman Sachs | 0.26% |
| 10 | Equitable | 0.17% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | GTCR LLC | 89.35% |
| 2 | BRAIDWELL LP | 5.69% |
| 3 | 12 West Capital Management LP | 4.96% |
| 4 | MACKENZIE FINANCIAL CORP | 4.31% |
| 5 | Renaissance | 2.40% |
| 6 | BlackRock | 2.07% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.93% |
| 8 | First Eagle Investment Management, LLC | 1.70% |
| 9 | Philosophy Capital Management LLC | 1.68% |
| 10 | T. Rowe Price | 1.41% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| GTCR | 20,150,005 | 13.76% | Proxy statement (DEF 14A), proxy filed April 24, 2026 |
| BlackRock | 9,345,268 | 6.38% | Form 13F, quarter ended March 31, 2026 |
| West Capital Management LP | 8,921,335 | 6.09% | Proxy statement (DEF 14A), proxy filed April 24, 2026 |
| 12 West Capital Management LP | 7,260,195 | 4.96% | Schedule 13G, filed May 15, 2026 |
| Vanguard Group | 7,166,528 | 4.89% | Form 13F, quarter ended March 31, 2026 |
| Renaissance Technologies | 4,264,689 | 2.91% | Form 13F, quarter ended March 31, 2026 |
| Stuart Feldman | 3,674,120 | 2.51% | Schedule 13G, filed August 13, 2026 |
| Morgan Stanley | 3,446,802 | 2.35% | Form 13F, quarter ended March 31, 2026 |
| Point72 | 3,205,496 | 2.19% | Form 13F, quarter ended March 31, 2026 |
| State Street | 2,428,717 | 1.66% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 146,426,000 shares outstanding, as reported by Maravai LifeSciences Holdings, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Maravai LifeSciences Holdings, Inc.'s shareholder meeting held May 26, 2026, in the 2025-2026 proxy season, 162 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 893 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF MARAVAI'S NAMED EXECUTIVE… — Maravai LifeSciences Holdings, Inc.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Maravai LifeSciences Holdings, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 29, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Maravai LifeSciences Holdings, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Maravai LifeSciences Holdings, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Maravai LifeSciences Holdings (MRVI) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/maravai-lifesciences-holdings-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.